Zepbound UK: Why It's Not Sold Here (and What Is)

You've seen it on TikTok, or in an American podcast, or in a comment thread where someone casually mentions the dose they're on. Zepbound. So you search Zepbound UK, and nothing quite adds up. No British pharmacy sells it. Your GP hasn't heard of it. The only sites offering it look faintly dodgy.

Here's the short version. Zepbound is a US brand name, and it was never launched here. The medicine inside it is already licensed and widely prescribed in Britain. It's just called something else.

Why isn't Zepbound available in the UK?

Nothing has gone wrong. No regulator blocked it, and there's no backlog holding it up.

Eli Lilly, who make tirzepatide, chose to sell it under two different brand names in the United States. Mounjaro is the version licensed there for type 2 diabetes. Zepbound is the version licensed there for chronic weight management. Same molecule, same pens, same doses, two labels.

Outside the US, Lilly didn't split it. One brand carries both uses. The NHS lists tirzepatide under the common brand name Mounjaro, and that licence covers type 2 diabetes and obesity.

So when someone in Ohio talks about starting Zepbound and someone in Oldham talks about starting Mounjaro, they may well be injecting exactly the same thing on exactly the same schedule.

Zepbound vs Mounjaro: what actually differs

Very little, and almost none of it is pharmacological.

The one genuine difference worth knowing about is sleep apnoea. In December 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnoea in adults with obesity, the first medicine approved there for the condition. The UK label hasn't followed, so Mounjaro is licensed here for weight management and type 2 diabetes rather than for sleep apnoea itself. In practice, sleep apnoea is one of the weight-related conditions that can make someone eligible for tirzepatide as an obesity treatment. The route exists. It's framed differently.

How tirzepatide works

It's a dual agonist, which means it mimics two gut hormones rather than one: GLP-1 and GIP. Semaglutide, the drug in Wegovy and Ozempic, acts on GLP-1 alone.

Those hormones do several things at once. They slow how quickly the stomach empties. They act on appetite centres in the brain. They prompt insulin release when blood sugar rises.

What most patients notice first isn't the scale, though. It's that eating stops being a negotiation. The constant low-level calculation about what's in the cupboard, what you'll have later, whether you can get away with it, goes quiet. For a lot of people that's the moment something genuinely shifts.

That quiet is also why the first few weeks can feel odd. You've spent years working against your appetite. Then it isn't there, and you have to learn to eat properly anyway. If you want the mechanism in more depth, we've written separately about how Mounjaro affects hormones and hunger.

What the trial evidence shows

The headline study is SURMOUNT-1: a phase 3 trial of 2,539 adults who had obesity, or overweight with a weight-related complication, and who did not have diabetes. They took tirzepatide or placebo once weekly for 72 weeks alongside lifestyle support.

At 72 weeks, the average change in body weight was:

• 5 mg: −15%
• 10 mg: −19.5%
• 15 mg: −20.9%
• Placebo: −3.1%

More than half of those on 15 mg (56.7%) lost at least a fifth of their starting body weight. Longer follow-up at 176 weeks showed the effect largely held, at −19.7% on the top dose.

Worth holding those numbers lightly. They're averages, from a trial with structured support and close monitoring, and real-world results spread much more widely in both directions. A meaningful minority of people don't respond well to tirzepatide at all. Going in expecting a range rather than a guarantee tends to make the first few months a lot less demoralising.

Can you get tirzepatide on the NHS?

Yes, though access is deliberately staged.

NICE recommends tirzepatide for managing overweight and obesity in adults under technology appraisal TA1026. NHS England then set out a phased rollout, starting with the groups at highest clinical need and prioritising by BMI combined with weight-related conditions such as type 2 diabetes, high blood pressure, heart disease or sleep apnoea.

Phased is the operative word. The programme is designed to widen out gradually over a period of years, so plenty of people who technically qualify will be waiting a long time for an NHS prescription. Anyone prescribed it in primary care also has to be offered wraparound support, with dietetic advice as a minimum.

Our guide to NHS eligibility for weight loss injections walks through the current criteria.

Getting tirzepatide privately in the UK

The other route is a private prescription from a UK-registered pharmacy after a clinical consultation. That's what most people currently taking tirzepatide for weight loss in Britain are doing.

A proper service will take your medical history, check your BMI, look for contraindications, verify your identity and your weight, and keep reviewing you as you titrate upwards. If a provider skips those steps, the absence is the warning sign.

Costs vary by provider and by dose. We compare them in our breakdown of the cheapest Mounjaro options in the UK, and we look at how tirzepatide sits against the other options in our guide to the best weight loss injections available here.

Buying "Zepbound UK" online: what you're actually getting

Be careful here, and that would be true even if you weren't reading it on a pharmacy's website.

If a site is shipping something labelled Zepbound to a UK address, one of a few things is going on. It's a personal import from the US, which puts you outside UK regulatory protection and outside any recall system if a batch goes wrong. It's a research-chemical vial sold with a disclaimer saying it isn't for human use. Or it's counterfeit.

The NHS puts it plainly: if you get a private prescription for tirzepatide, buy it from a registered pharmacy, because some websites sell fake weight loss medicines. You cannot tell a convincing fake by looking at the box.

A few checks before you order anything:

• The pharmacy should appear on the General Pharmaceutical Council register, with its registration number shown on the site
• There should be a named superintendent pharmacist
• A real consultation should happen before any prescription, not a tick-box form
• A UK-licensed product arrives branded Mounjaro, not Zepbound
• If the price sits dramatically below everyone else's, treat that as information

Doses, side effects and the first few weeks

Tirzepatide starts at 2.5 mg weekly. That's a starting dose rather than a treatment dose, and it increases in 2.5 mg steps no sooner than every four weeks, up to a maximum of 15 mg. Most people settle somewhere in the middle rather than climbing all the way.

Common side effects are mainly gastrointestinal: nausea, constipation or diarrhoea, stomach pain, tiredness, injection-site reactions, and sometimes hair thinning. They tend to be worst in the days after a dose increase and to ease as your body adapts. Titrating slowly genuinely helps, and there's no prize for reaching 15 mg quickly.

Rarer but serious risks include pancreatitis, gallbladder problems and severe allergic reactions. Severe pain in the stomach or back that doesn't settle needs urgent medical advice rather than a wait-and-see.

Two things catch people out.

Contraception. The NHS advises using additional barrier contraception for four weeks after starting tirzepatide, and for four weeks after each dose increase, because slowed stomach emptying can affect how the oral contraceptive pill is absorbed.

Surgery and anaesthetic. Tell anyone involved in an operation or dental procedure that you're taking tirzepatide, because of the risk of stomach contents being aspirated under sedation or general anaesthetic.

For the fuller picture, see our guides to Mounjaro side effects and whether Mounjaro is safe, plus the practical detail in our UK Mounjaro dosage guide.

Moving to the UK while already taking Zepbound

This comes up more than the search data suggests, and it's the scenario nobody writes about.

If you've been prescribed Zepbound in the US and you're relocating, your American prescription won't be dispensed here. UK pharmacies can only dispense against a prescription written by a prescriber registered in the UK, and the product they'd hand over is Mounjaro.

The practical upside is that there's no switch to manage. The active ingredient is identical and the dose ladder is identical, so if you were stable on 10 mg of Zepbound, 10 mg of Mounjaro is the same weekly dose of the same drug. You shouldn't need to restart at 2.5 mg or titrate up again, though a UK prescriber will want to see evidence of what you've been taking and for how long before continuing you at that dose.

Two things to sort out before you fly:

• Ask your US prescriber for a written summary of your current dose, start date and any side effects, which makes continuing here much simpler
• Build in a buffer, because arranging a UK consultation and first delivery takes longer than most people assume, and an unplanned gap of several weeks often means titrating back up

Our guide to where to inject Mounjaro covers the practical side once you're set up, and the pens and technique are the same either side of the Atlantic.

If tirzepatide isn't right for you

It isn't the only option, and it isn't automatically the best one for everyone.

Semaglutide, sold here as Wegovy for weight management, acts on GLP-1 alone. Average weight loss in the trials is somewhat smaller, but it suits some people better, particularly those who find tirzepatide's side effects hard going. Our Wegovy versus Mounjaro comparison puts the two side by side.

And whichever medicine you end up on, the question that matters most tends to arrive later: what happens when you stop. Appetite comes back, and weight usually follows unless something else has changed alongside the medication. Better to think about that at the start than at month twelve. We've written about what happens when you stop taking Mounjaro if you want to look ahead.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.